MYC Amplification

CI-VAR-00000237Explore in graph →CIViC 2564

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 3 cancer contexts on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Esophageal Carcinoma1
MYC Amplification	Ibrutinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID6928 This study found the clinical BTK/ERBB2 kinase inhibitor, ibrutinib, downregulated ERK-mediated signal transduction, cMYC Ser-62 phosphorylation and levels of MYC protein, and elicited G1 cell cycle a… (full text at CIViC) PMID 28830912 · Chong et al., 2018 · Open in CIViC	civic
Lung Adenocarcinoma2
MET Amplification AND MYC Amplification	Capmatinib	Predictive	C	Supports Resistance	3	submitted	EID11420 An 82-year old male (smoker: 60 pack-years) was diagnosed with lung adenocarcinoma. Initial tumor tissue testing revealed MET amplification (GCN = 13.5). The patient was enrolled in a phase 2 trial an… (full text at CIViC) PMID ·

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.

Medulloblastoma1
MYC Amplification	(prognostic)	Prognostic	B	Supports Poor Outcome	5	submitted	EID7048 Group 3 medulloblastomas with MYC amplifications are often associated with large cell/anaplastic histology, young patients, and overall poor prognosis. PMID 15328187 · Lamont et al., 2004 · Open in CIViC	civic